Monitor for future financial disclosures that may reflect the cost of this executive hire; watch for potential stock dilution from RSU issuance once Form S-8 is filed.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $5.03entry
- T+1 · 9mo ago +8.35%α +8.90% · $5.45
- T+5 · 9mo ago +8.55%α +9.65% · $5.46
- T+20 · 8mo ago +8.55%α +13.78% · $5.46
- T+60 · 6mo ago +55.86%α +48.91% · $7.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026. Huston receives an annual base salary of $540,000 and an inducement grant of 220,000 restricted stock units, with vesting over four years. The appointment reflects a strategic leadership addition in the biotech firm's financial management.
Key Facts
- Thad Huston appointed CFO effective February 18, 2026
- Annual base salary of $540,000 with 40% target bonus
- Inducement grant of 220,000 RSUs under 2025 Inducement Plan
- RSUs vest over four years: 25% on February 15, 2027, then quarterly
- Employment Agreement includes severance terms for termination without Cause or for Good Reason
Financial Impact
Approximately $540,000 annual cash compensation plus $2.2 million in RSUs (based on current market value assumptions, not disclosed in filing)
Risk Factors
- Potential dilution from issuance of 220,000 RSUs
- Leadership transition risk during integration period
- Increased operating expenses from new executive compensation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ARTV), Batch item 1 | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index-headers.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509.txt | 0001193125-26-067509 |
| 8-K Filing (ARTV), Batch item 5 | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index-headers.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509.txt | 0001193125-26-067509 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers